Location, spreading and oral corticosteroids are associated with insomnia in vitiligo patients: A case–control study

4Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Vitiligo can cause disfiguration, impair the social function of the patients and induce physiological burdens. However, limited research about the health-related quality of life has been conducted in vitiligo patients’ sleeping conditions. Objective: To evaluate the prevalence, severity, and risk factors of insomnia in vitiligo patients. Methods: This case–control study was performed in March 2021. An online survey questionnaire including baseline information and the sleep-related instrument was sent to 762 vitiligo patients. The vitiligo-related evaluation was conducted by online video interview. According to whether having insomnia or not, patients were grouped and compared their clinical and demographic characteristics. The logistic regression model was conducted to analyze the risk factors for insomnia. Results: A total of 409 patients were included. About 49.9% of patients (204/409) experienced insomnia. About 55.9% (114/204) of the insomnia in vitiligo patients was adjustment sleep disorder caused by vitiligo. Development, aggravation, or recurrence of vitiligo were deemed as the first reason for insomnia in 71.1% of the sample (81/114). There were significant differences in age (32.1±4.1 vs 27.9±4.2 years, P < 0.001), the percentage of female (62.8% vs 49.3%, P=0.006) and working in the urban areas (77.0% vs 66.3%, P = 0.017), vitiligo in face and neck (67.2% vs 48.8%, P < 0.001), progression in vitiligo (65.7% vs 49.3%, P=0.001), oral corticosteroids (25.0% vs 16.6%, P=0.036) and depression (5.4% vs 0.5%, P = 0.003) between groups. After adjusting for gender, age and comorbidity, the multivariate logistic regression revealed that vitiligo in face and neck (OR=2.62; P=0.032), progression in vitiligo (OR=2.50; P=0.002), and oral corticosteroids (OR=2.71; P=0.021) remained risk factors for insomnia in vitiligo patients. Conclusion: Insomnia is prevalent in vitiligo patients. Dermatologists should identify this condition carefully, especially humanistic factors in social life, and perform individualized “non-drug” treatment.

Cite

CITATION STYLE

APA

Liu, J. W., Tan, Y., Chen, T., Liu, W., Qian, Y. T., & Ma, D. L. (2021). Location, spreading and oral corticosteroids are associated with insomnia in vitiligo patients: A case–control study. Clinical, Cosmetic and Investigational Dermatology, 14, 971–980. https://doi.org/10.2147/CCID.S322963

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free